论文部分内容阅读
目的观察短期胰岛素强化治疗新诊断重症T2DM患者治疗效果。方法对131例新诊断重症(FPG≥11.1mmol/L和/或2hPG 14.0mmol/L)T2DM患者随机分为持续皮下胰岛素输注(CSII)组和多次皮下注射胰岛素(MSII)组,进行胰岛素强化治疗2周,观察两组治疗达标时间、胰岛素用量及发生低血糖情况。结果与MSII组相比较,CSII组血糖达标时间明显缩短(P<0.01)、CSII组胰岛素用量显著低于MSII组(P<0.01)、CSII组低血糖发生率低(P<0.05)。结论 CSII较MSII临床治疗效果好、血糖达标快、胰岛素用量少、低血糖发生率低。
Objective To observe the effect of short-term insulin intensive therapy in newly diagnosed severe T2DM patients. Methods Thirty-one newly diagnosed T2DM patients with newly diagnosed severe (FPG ≥11.1mmol / L and / or 2hPG 14.0mmol / L) T2DM were randomly divided into continuous subcutaneous insulin infusion (CSII) group and multiple subcutaneous injection of insulin (MSII) Intensive treatment for 2 weeks, observe the treatment time, insulin dosage and occurrence of hypoglycemia in both groups. Results Compared with MSII group, the time to blood glucose compliance was significantly shorter in CSII group (P <0.01). The insulin dosage in CSII group was significantly lower than that in MSII group (P <0.01). The incidence of hypoglycemia was lower in CSII group (P <0.05). Conclusion CSII is more effective than MSII in clinical treatment, achieving fast blood glucose level, less insulin dosage and low incidence of hypoglycemia.